Regadenoson

Drugbox
IUPAC_name = 1- [6-amino-9- [(2"R",3"R",4"S",5"R")-3,4-dihydroxy-5- (hydroxymethyl)oxolan-2-yl] purin-2-yl] - "N"-methylpyrazole-4-carboxamide

---

CAS_number = 313348-27-5
CAS_supplemental = CAS|875148-45-1
ATC_prefix =
ATC_suffix =
ATC_supplemental =
PubChem = 219024
DrugBank =
chemical_formula =
C=15 | H=18 | N=8 | O=5
molecular_weight = 390.354 g/mol
synonyms = 2- [4- [(methylamino)carbonyl] - 1"H"-pyrazol-1-yl] -adenosine
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
licence_US = Regadenoson
pregnancy_AU =
pregnancy_US = C
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US = Rx-only
legal_status =
routes_of_administration = Intravenous

Regadenoson (INN, codenamed CVT-3146) is an A_2A adenosine receptor agonist that is a coronary vasodilator.

It was approved by the United States Food and Drug Administration on April 10, 2008 and it will be marketed under the tradename Lexiscan. [ [http://www.astellas.us/press_room/docs/FINAL_LEXISCANAPPROVAL041008.pdf CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM) ] ] It has not yet gained approval in the European Union.

References